Since their initial transmission to humans, viruses have diversified extensively through recombination and mutation. The presence of intra-and inter-individual viral diversity influences disease progression, drug resistance, and therapy and presumably explains the conflicting results in many studies, including the failure of peptide-based vaccination strategies. Although HIV is a small RNA virus, coinfection with large DNA viruses, notably the oncogenic γ γ-herpesviridae human herpesvirus-8 and Epstein Barr virus, is common. This coinfection occurs secondary to immunosuppression and shared transmission routes with high-risk predisposing behavior. In addition, all 3 of these viruses can lead to chronic infections, long periods of latency, and reactivation characterized by pain and suffering. The efficient targeting of their genetic diversity represents one of the major challenges in their control, both in prophylactic and therapeutic strategies. An understanding of diversity will help delineate whether population-specific vaccine strategies are necessary.
Origins of HIV, KSHV, and EBV
Although numerous viruses infect humans, the specific dissemination of HIV-1 in humans over the past 4 decades represents the most catastrophic example of genome transmission, emergence, propagation, and expansion. 1, 2 The interaction between hosts and their infecting pathogens has been likened to a "molecular arms race," [3] [4] [5] and in this particular competition, our lentiviral opponent appears able to run very fast indeed. The reverse transcriptase error frequency, 6, 7 the production of in excess of 10 9 virions per day in vivo, the large number of affected individuals, and the persistence of infection afford HIV-1 tremendous scope for the generation of "star-burst" diversity. 1, 8 Diversity in herpesviruses is less extreme, and interestingly there are few or no postulated mechanisms that adequately explain herpesvirus differences observed, in the absence of an error-prone proofreading system. 9 The earliest documented case of infection with HIV-1 was identified in a sample stored in 1959 from the city now known as Kinshasa in the Democratic Republic of Congo. 10 Assuming that the evolutionary behavior of the virus has been consistent over time, it has been possible to use the wealth of available HIV-1 sequence data from viruses with known dates of sampling to model virus diversification and to estimate the timing of important events in the virus' past. In this way, Korber et al 11 proposed that the main (M) group of HIV-1 strains that are currently infecting the human population began to diversify around 1930 (95% confidence intervals 1915-1941) 11 . The most probable source of HIV in humans is the inadvertent introduction of a simian immunodeficiency virus (SIVcpz) from a closely related primate species, notably the common chimpanzee Pan troglodytes (see the left panel of Figure 1 , next page). 12 In 1986, a second retrovirus strain, known as HIV-2 and having approximately 40% to 60% homology with HIV-1, was isolated from patients with AIDS from West Africa. Careful studies of HIV-2 genomes showed that there is a remarkably close relationship between HIV-2 and SIV strains that infect sooty mangabeys (Figure 1 , right main image; SIVsm). It is believed that there have been at least 3 separate entries of SIVsm into the human population. 13 Using maximum likelihood methods that take into account the molecular clock and coalescent theories with known sampling dates, 14 it has similarly been able to show that HIV-2 diversified in humans in the mid-1940s. 15 Members of the Herpesviridae family are important human and animal pathogens, implicated in the pathogenesis of primary effusion lymphoma, multicentric Castleman's disease, and all epidemiological forms of Kaposi's sarcoma (classic, African endemic, posttransplantation, and AIDS-associated), and they have 1 of the largest DNA genomes among known mammalian viruses with up to 200 potential open reading frames, the majority of which overlap. Unlike HIV, whose genome codes for unique genes, functional characterization of these genes, accomplished by generating virus mutants and investigating resulting changes in phenotype, is important for understanding molecular aspects of herpesvirus replication and pathogenesis and may also, as for HIV, provide a basis for the rational development of new vaccines and chemotherapeutics. 16, 17 Lack of variability in their genomes has not allowed maximum likelihood analyses of progenitor species and times, but it seems probable that these large viruses have persisted for millennia, unlike the situation with HIV. Evidence for this derives from the large number of human homologues in the γ-herpesviridae human herpesvirus-8 (HHV-8; also known as Kaposi's sarcoma-associated herpesvirus, KSHV) and Epstein Barr virus (EBV) genomes, pirated from their hosts in the course of evolution. 18 These pirated genes, adapted over time, have been used to facilitate viral transmission and survival. 19 Their preponderance in immunocompromised HIV-1 seropositive hosts also attests to the importance of immune surveillance in their control, in terms of both reactivation and new infection. 20, 21 Despite their differences, 5 lines of evidence substantiate the zoonotic origins of all of these viruses 13, 22 : (1) similarities in viral genome organization between HIV and SIV, and between primate and mouse herpesviruses and HHV-8 and EBV; (2) phylogenetic relatedness ( Figure 2 ); (3) prevalence in the natural host; (4) geographic coincidence; and (5) plausible routes of transmission (monkeys have been hunted, eaten, and kept as pets for hundreds of years). However, one notable feature of some of the related viral infections in animals such as chimpanzees or sooty mangabeys is the lack of progressive AIDS-like disease in their natural host.
It is thought that many millenia ago, a cataclysmic event occurred in the chimpanzee population such that the immunological diversities expressed by its major histocompatibility complex (MHC) class I molecules were reduced by more than 90%. This was probably the result of the introduction of a retroviral infection similar to HIV in this population, although selection by a herpesvirus would also be possible and difficult to prove or disprove. 23 Some consider that we may be seeing the evolution of a similar event in humans with the HIV epidemic continuing out of control and the only long-term survivors without treatment being those with a very narrow spectrum of genes acting in concert to control the deleterious effects of HIV infection. This highly pessimistic scenario is to some extent counterbalanced by the prognostic transformation of those infected with HIV who have received highly active antiretroviral therapy (HAART).
Developing more effective prophylactic and therapeutic strategies against mutable viruses that are integrated into the genome of crucially important populations of cells (memory CD4 T cells in the case of HIV, memory B cells in the case of γ-herpesviridae) poses one of the major medical challenges of this century. Since their initial expansion, virus types, strains, groups, subtypes, and mosaics of these have diversified extensively through mutation and recombination. Although increasing attention is being given to developing regimens that focus on specific viral strains, an understanding of the genetic diversity of viruses has been identified as one of the main challenges in overcoming viral pandemics.
Genetic Diversity and Evolution
HIV HIV-2 was the first human virus for which the 5 "zoonotic" criteria mentioned above were fulfilled. 13 Indeed, HIV-2 types infecting humans have been found to comprise 6 different phylogenetic lineages, groups (formerly known as subtypes) A through to F, described in some detail at the Los Alamos database run by Bette Korber (http://hiv-web.lanl.gov). The worldwide HIV pandemic is, however, caused almost entirely by HIV-1 ( Figure 3A) .
Current data suggest that HIV-1 comprises 3 distinct virus groups termed M (the main group), O (the outlier group), and N (the non-M, non-O group). 24, 25 The M group causes the majority of disease and infections and consists of 11 clades. Evidence indicates that the SIV counterparts of HIV-1 and HIV-2 were introduced into human populations (and those populations inevitably have a high mix of MHC types) no less than 7 times, maybe more. Yet, the HIV-1 group M viruses appear to have arisen through just one crossspecies transmission event. 12 The identification of new HIV-1 clades and the realization of the existence of circulating intersubtype recombinant forms have led to alterations in classification. 25 As mentioned, HIV-1 infections on a global scale are generally caused by group M viruses. Group O viruses are limited to people living in or epidemiologically linked to central Africa, particularly the Cameroon and its neighbors, where the highest diversity of HIV-1 can still be observed. However, even in this area they represent a small minority of HIV-1 infections. Only a few cases of group N infections, all from Cameroon, have ever been reported.
Within group M, subtypes are recognized, identified by the letters A-D, F-H, J, and K, all of which are thought to have originated in central Africa. Subtypes form clusters roughly equidistant with each other in phylogenetic trees. Within the A and F subtypes, separate subclusters are distinguished, designated sub-subtypes (or subclusters) A1 and A2, and F1 and F2, each pair of sub-subtypes being more closely related to each other than with other subtypes. Some subtypes share a geographic localization, whereas others appear to have a similar ancestry, examples including subtype G viruses from Spain and Portugal, subtype B viruses from Thailand, and subtype C viruse from areas as geographically diverse as India and Ethiopia. [26] [27] [28] [29] When 3 epidemiologically unlinked individuals have intersubtype recombinant HIV viruses within them identified by full-length genomic sequencing (close to 10 kilobases for each), the new virus formed is designated a circulating recombinant form (CRF). 25 first CRF was originally identified by full-length sequence analysis of viruses from central Africa and Thailand. 24, 30 A large portion of this virus' genome derives from subtype A, suggesting its origin by recombination between this subtype and an as yet unidentified subtype E. CRFs are identified by numbers correlative to the order of their discovery followed by the letters of the parental subtypes (U indicating unclassified segments), or cpx (from complex) for recombinant viruses thought to derive from 3 or more parental subtypes. At the time of writing, 17 CRFs have been reported, the majority of these being of African origin. 31, 32 Five of the 17 appear to have originated outside Africa, especially in areas where parental strains circulate; CRFs in the global HIV-1 pandemic represent more than 20% of new infections in recent studies. [33] [34] [35] The first HIV virus identified and the main genetic form in western and central Europe, the Americas, and Australia is sub-type B. 36 As a result, most cladespecific vaccines thus far studied have used sequences based around this relying on cross-clade immune responses in the case of infection with other subtypes 37, 38 ; this also applies to peptide vaccines. 39, 40 On a worldwide scale, the most prevalent HIV-1 genetic forms are subtypes C, A (sub-subtype A1), B, and CRF02_AG ( Figure 3A ). Most infections in countries in sub-Saharan Africa, China, India, and Ethiopia are caused by subtype C, which is also circulating as a minor form in Brazil and Russia. Recombinant viruses with subtype C portions are common in Tanzania, and 2 CRFs with predominantly subtype C genomes, CRF07_BC and CRF08_BC, are prevalent among injecting drug users in China. 28 Subtype A viruses are predominant in areas of central and east Africa (Kenya, Uganda, Tanzania, and Rwanda) 41 and in east European countries formerly constituting the Soviet Union, 42 where they are mainly transmitted among injecting drug users, and they are not uncommon in west Africa. Throughout all of west Africa and in parts of central Africa, however, the most prevalent genetic form is a recombinant virus, CRF02_AG. CRF01_AE now better known as envelope subtype E, of central African ancestry, is widely circulating in southeast Asia. 43, 44 Originally propagated in the late 1980s by sexual contact in Thailand, this genetic form has become prevalent also among injecting drug users in this country and has propagated to all countries in the vicinity, including China, Japan, and Korea. 43 HIV-2 lineages originated near Senegal and the other Ivory Coast countries, adjacent to the epicenter where most sooty mangabeys are found. All HIV-1 subtypes are thought to have originated in central Africa, near the Congo, where many chimpanzees live. 45 KSHV and EBV Although many proteins and epitopes within EBV can avoid an immune response in a classical "CTL escape manner," variation in DNA viruses is significantly less than for HIV. EBV has been classified into 2 different types according to the organization of the EB nuclear antigen 2 (EBNA2) gene region. Type A virus hybridizes with probes from B95-8 or M-ABA viruses and the B type virus with probes from the Jijoye virus strain. In EBV, only the EBNA-1 gene is highly variable. This high frequency of sequence variation within functionally important domains of EBNA-1 has led to the identification of 5 EBV subtypes. 46 Individuals may be infected with multiple EBV strains (classified according to EBNA-1 subtype), but interestingly Burkitt's lymphomas carry a single subtype and exhibit some subtype preference. Subtype variation has also been related to geographical location in some cases although the clinical significance of strain mutants remains unclear.
For HHV-8, the situation is more complex. At the far left-hand end of its 140-kb double-stranded DNA episome lies a unique gene encoding a 46-kDa transmembrane type I glycoprotein, K1, containing a sequence that functions as an immunoreceptor tyrosine-based activation motif (ITAM). 47-50 K1, expressed predominantly in the lytic viral life-cycle, appears able to couple extracellular signals to multiple intracellular signaling pathways in response to ligand-receptor interactions, which in turn leads to cellular responses, including proliferation, differentiation, and death. 51, 52 K1 is also able to transduce signals in the absence of exogenous cross-linking ligands and can orchestrate the expression of an array of transcription factors involved in cellular activation that may ultimately lead to growth dysregulation. As such, K1 appears capable in vitro and in vivo of inducing cellular transformation. 48, 53, 54 Although the great majority of the HHV-8 genome is conserved, K1 is variable ( Figure 3C ). 55 The variability of K1, with a massive preponderance of amino acid altering (nonsynonymous) mutations, has been known for some time. 49, 50, 56 More recently, it has been shown that at an individual codon level, specific sites in K1 appear to undergo a considerably greater positive selective pressure than sites in other highly variable mammalian or viral genes, such as the 58 codons in exons 2 and 3 that comprise the antigen recognition site of major histocompatibility complex (MHC) class I and the 34 codons in the V3 loop of HIV-1 env (irrespective of evolutionary time scale). 57 The presence of clusters of MHC class I restricted epitopes within K1 has been cited as putative evidence that pressure from CD8-positive cytotoxic T lymphocytes may help drive this gene's extreme variability and positive selection.
However, in the absence of an error-prone polymerase (as for HIV), there are no known mechanisms to explain this. DNA-virus DNA polymerases do not perform the template switches required to generate such diversity. 58 Furthermore, K1 does not appear to change over time within an individual, nor does it differ between different tumor sites within the same patient, quite unlike the situation observed with retroviruses. 59, 60 The HHV-8 A strain is found in Northern Europe and America, the B strain (thought to be the most ancient) is from Africa, and the C strain, often associated with classical Kaposi's sarcoma, is found in Mediterranean countries ( Figure 3B) 61, 62 ; a KSHV D strain containing nucleotide insertions has also been recently described (mainly from South America and the Pacific Islands). The evolution and changes in these strains are thought to reflect patterns of migration commencing in Africa shown in this figure, with bottlenecks at appropriate times in human evolution. 49, 50, 56, 63 This is in stark contrast to the geographical distribution of HIV subtypes that reflects the sexual patterns of the past few decades rather than eons of human evolution.
Clinical Significance For HHV-8 and EBV, the significance of diversity has not yet been useful clinically. Although strain-specific peptide vaccines are discussed, clinical trials have not been undertaken because the pernicious effects of these viruses are often thought to be a secondary consequence of immunosuppression as opposed to primary viral infection. In childhood, such infections may "shape and mature" the immune system. For HIV the situation is different, and control of HIV is likely to lead to control of overwhelming herpesvirus infections and secondary neoplasia, although EBV-positive lymphomas in HIV seronegative individuals remain a common neoplasm.
CRFs can be used to track the dissemination of the global HIV pandemic. The world map ( Figure 3A) illustrates that most CRFs are present in Africa, whereas in other locations only a few are present. This distribution suggests that the initial HIV-1 spread was initiated by a few individuals, which led to a founder effect translating to rapid spread of a single CRF or subtype in a defined risk group (ie, B subtype in men who have sex with men in America and A subtype in intravenous drug users in Russia). 64 In Thailand, 2 separate outbreaks occurred simultaneously with subtype B and CRF01_AE, but their presence occurred in 2 different risk groups: intravenous drug users were infected with subtype B and heterosexual contacts with CRF01_AE (A and E being two recombined subtypes). This indicates that the source case for the intravenous Thai drug users was Europe, Russia, the United States, or Australia, and the heterosexual risk group was from Africa. 42, 44, 65 In addition to CRFs, several HIV-1 recombinant viruses with unique mosaic structures, seen in a few epidemiologically linked persons, have been reported. 43, 66, 67 In Argentina, second-generation BF recombinants, deriving from recombination of CRF12_BF with subtype B viruses, are possibly more prevalent than the circulating recombinant form. 24, 67, 68 These data suggest the possibility of reinfection with a different subtype, as shown in a recent dramatic description. 69 The presence of an important number of different unique recombinants in some studies has led to the proposition that superinfection is not such a rare event. 69, 70 
Superinfection
In one report, a patient who was treated with antiretroviral drugs soon after becoming infected with HIV-1 (M group) had suppression of viremia leading to supervised or structured treatment interruptions (STI), a well-described therapeutic strategy. 71 This stop-start procedure was repeated twice more, for a total of 3 treatment-free periods. Altfeld et al 69 found that, during the first 2 of these periods, the patient's immune system controlled replication of the virus well for several months, in stark contrast to the situation normally observed in those who receive HAART in infection, where on stopping therapy, virus levels normally rebound to those seen before treatment within weeks. 69 Viral control during STI is thought to occur through enhancement of the immune response to HIV-1, particularly the response of CD8+ T lymphocytes that kill HIV-infected cells. Indeed, the CD8+ T cells from the patient studied by Altfeld et al 69 showed an excellent response, with some 6% recognizing and proliferating in response to HIV-1 proteins in tetrameric analyses. His CD4+ T cells also proliferated markedly when exposed to HIV proteins in vitro-an unusual scenario in HIV-infected people.
During the third STI, virus levels rebounded more rapidly than before, and the response of CD4+ T cells deteriorated. On further investigation, it was found that a new virus variant had emerged toward the end of the second treatment-free period. Although both were from the same HIV-1 B clade, the new virus had notable sequence differences. An analysis of responses to 16 known clade B HIV-1 human leukocyte antigen (HLA) class I binding epitopes, recognized by CD8+ T cells, found that 7 differed by at least 1 amino acid between the original and the new virus and, most important, the T cells could not detect these new epitopes. The other 9 epitopes were the same, and the responses of CD8+ T cells to them were maintained but these responses failed to control the virus.
Further analysis of the sequence of the second virus showed that this variant was a distinct strain and probably a new infection, a superinfection, and the patient himself reported a recent episode of sexual exposure that was followed by a fever-associated seroconversion type illness. In this single case report, superinfection took place despite a good HIV-specific immune response.
On the basis of this 1 patient, it is difficult to know how often such events occur. There is a possibility that the second virus remained hidden in lymph nodes from the outset, a situation not in fact uncommon in women, 72 and the greater significance of gender specific differences in HIV remains unknown but a potentially fruitful area of further research.
Although more than 1 EBV or KSHV strain can infect an individual host, 59 their clinical significance remains undetermined.
Vaccine Development and Therapeutic Response
Candidate vaccines have been developed with a clade and/or subtype specificity (for example the International AIDS Vaccine Initiative trials, which can be found at www.iavi.org/trials), and these are thought to rely on the generation of a CD8+ T cell response, although generation of a T-helper cell and B-cell antibody response are also desirable. 2, 73 The importance of generating a CD8+ memory response derives from data demonstrating that (1) there is a rise in viral load after CD8-blocking antibodies are infused into macaques infected with SIV, 74 (2) viral mutation to escape CD8+ T cells occurs in HIV and SIV infections, 74 (3) long-term nonprogressors maintain good CD8 responses, 76, 77 and (4) sex workers who are frequently exposed to HIV seem to be resistant to HIV infection and generate anti-HIV responses through CD8+ T cells. 78, 79 It is often difficult to draw conclusions regarding susceptibility to HAART and many studies produce conflicting results, 80,81 a major criticism being that studies are too small. Genetic changes in the viral swarm occur rapidly, particularly when selective pressure is applied by prescribing drugs. 79, [82] [83] [84] Thus the development within this pool of variants with reduced sensitivity to a particular drug is an important cause of drug failure. This may also occur as a result of selection of minority species already present because of continuing viral replication in the presence of drug selective pressure. 85, 86 Mathematical modeling indicates that the former is more important, [87] [88] [89] particularly the single or double mutations that are pre-existing in the viral population, which confer high levels of drug resistance.
With current HAART combinations, viral replication is suppressed sufficiently in theory, to make the generation of new mutations in the virus unlikely. 75, 79 Group O viruses are thought to be naturally resistant to non-nucleoside reverse transcriptase inhibitors, and group N viruses have not been phenotypically studied in detail. 90 For the M group, data have suggested that protease inhibitor mutations are more common at baseline in non-B subtypes, with a decreased response to HAART. 91 In a Zambian study (n = 28) examining the prevalence of drug resistance and evolutionary changes in sequence, only secondary but no primary drug-resistant mutations were observed. 92 Two London-based studies, one at King's 93 and one at Imperial College, 94 have failed to demonstrate that the presence of particular subtypes, individual polymorphisms, and mutation combinations are associated with either a decreased response to HAART or a worse prognosis.
The interactions between adherence to medication and the development of resistance are complex. [95] [96] [97] Individuals who take very little medication are likely to fail therapy with wild-type virus present in the circulation. 98, 99 It is likely that intermediate levels of adherence, which allow virus with reduced sensitivity to drug to replicate more rapidly than wild-type, are most likely to be associated with the selection of resistance mutations. Following complete suppression of viral replication with drugs, occasional nonadherence may be relatively unimportant to the generation of resistant mutations, because Darwinian selection may not occur at low rates of viral replication. 74, 100 It has been suggested that HIV-1 subtypes and CRFs could influence viral transmissibility and even the controversial area referred to as "fitness." Here, differing replication rates may influence disease progression, drug resistance, and response to therapy. However, the numerous other factors that influence these features make it difficult to establish the true effect of viral subtypes.
Summary
The impact of viral diversity on drug and vaccine development remains uncertain. The race appears to be against a whole team of fast runners as opposed to one single swift opponent, and our chances of fulfilling former United States President William J. Clinton's 1997 declaration of a vaccine within 10 years appears to decrease in proportion to the number of teams of competitors.
The major biological obstacles to the development of a preventive vaccine are (1) the fact that HIV incorporates its DNA into active sites of the hosts' chromosomes, leading to persistent infection for the life of that cell and its progeny and often the destruction of those cells; (2) the lack of a small, readily available animal model; (3) the fact that HIV uses the same immune activation pathways required for successful vaccination for its own replication; and importantly and crucially (4) the profound genetic variability of HIV, with up to 30% amino acid differences between subtypes, meaning that an effective vaccine must be broadly active to prevent emergence of resistant viruses. Some but not all of these features are shared by tumor-causing DNA viruses such as EBV and KSHV, although these cause less of a problem worldwide.
Viral epidemics on a global scale are evolving: their spread has been referred to as a travel history whose epidemiology can be tracked by genetic, immunological, and molecular tools. For HIV, travelassociated infections are now mainly caused by non-B subtypes and CRFs, and these contribute to an increase in HIV-1 diversity, particularly across Asia, South America, and Central America; in turn, this has led to new recombinant forms. Emergence of HIV-1 mutated strains with resistance to 1 or more antiretroviral drug classes remains an important cause of treatment failure. The increasing prevalence of multidrug resistance forewarns new problems in sustaining the effectiveness of HAART, although new drug classes do not necessarily target the HIV protease or reverse transcriptase enzymes, and advances in genotypic and phenotypic testing allow for drug resistance-guided therapeutic management.
The advances being made with HIV, both in drug and vaccine design, and the clinical importance of subtype identification will probably have a use in the control of EBV and KSHV infections. The emergence of new viruses such as avian influenza and the SARS Coronavirus does not diminish the importance of ancient pathogens, especially those that persist long enough in their hosts to cause cancer. Type-specific therapeutic vaccines that modulate the course of infection may appear on the horizon, but cross-reactivity, as in the case of the new human papillomavirus vaccines, may allow for a vaccine that is effective in 1 population to have efficacy across the planet.
